Sumanta K. Pal, MD

Sumanta K. Pal, MD, associate professor of the Department of Medical Oncology and Experimental Therapeutics at City of Hope, discusses the data he considers when treating patients with metastatic urothelial carcinoma.

While many agents have been approved for this disease, Pal says the decision will rely heavily on the physician&rsquo;s comfort level with each of the agents when deciding which to use.

In Pal&rsquo;s opinion, there is the highest amount of evidence with atezolizumab (Tecentriq) and pembrolizumab (Keytruda). When looking at data for atezolizumab from the IMvigor211 trial, many physicians found the results to be negative. However, one particular subset of patients in this study was given atezolizumab in comparison to agents like taxanes.

Videos

Treatment Considerations for Patients With Metastatic Urothelial Carcinoma

Sumanta K. Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses choosing second-line therapy for patients with urothelial carcinoma.

Sumanta K. Pal, MD | Authors

Articles

Treatment Considerations for Patients With Metastatic Urothelial Carcinoma

Choosing Second-Line Therapy for Patients With Urothelial Carcinoma